TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23554054

Group type: EXPERIMENTAL
Intervention: Folic acid (400μg/day, n = 6)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (n = 8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Folic acid compared to placebo
Number of subjects: 14
Study: 19952781

Group type: EXPERIMENTAL
Intervention: Riboflavin 1.6 mg per day for 16 weeks
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 18782344

Group type: EXPERIMENTAL
Intervention: Aripiprazole (up to 15 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16640610

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) + Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 351

Group type: COMPARATOR
Intervention: Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) or Amodiaquine + Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Amodiaquine + Sulphadoxine-Pyrimethamine (SP)
Number of subjects: 351
Study: 12745487

Group type: EXPERIMENTAL
Intervention: Behavioral treatment and nicotine replacement therapy (gum, patch, or inhaler) to reduce smoking by 50% over 4 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Usual-care (brief advice to quit and nicotine replacement if they decided to quit)
Number of subjects: 67
Study: 11910264

Group type: EXPERIMENTAL
Intervention: 5-HTP 100 mg with carbidopa 100 mg and 50 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5-HTP 100 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5-HTP 200 mg
Number of subjects: 12
Study: 10328437

Group type: COMPARATOR
Intervention: recombinant human erythropoietin (rhEPO)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: recombinant canine erythropoietin (rcEPO)
Number of subjects: 13
Study: 7488373

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin hydrochloride (200 mg/mL), 24 patients
Number of subjects: 44

Group type: COMPARATOR
Intervention: Gentamicin sulfate (5 mg/mL), 20 patients
Number of subjects: 44
Study: 2031210

Group type: EXPERIMENTAL
Intervention: Hospital doctors providing information about illness and death to cancer patients
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Hospital doctors' communication practices
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Support and information provided by professionals to relatives
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Role of hospital doctors vs general practitioners in providing information
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Situations of 'closed awareness'
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Nurses and hospice practitioners' involvement in breaking bad news
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Relatives' perceptions of communication
Number of subjects: 639

Group type: EXPERIMENTAL
Intervention: Gaps in information provided to relatives
Number of subjects: 639
Study: 7036816

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir at 750 mg/m2 body surface area per day for 7 days
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir
Number of subjects: 34
Study: 31411099

Group type: EXPERIMENTAL
Intervention: GONAL‐f® injector
Number of subjects: 180

Group type: COMPARATOR
Intervention: Bemfola® injector
Number of subjects: 180

Group type: COMPARATOR
Intervention: Rekovelle® injector
Number of subjects: 180

Group type: COMPARATOR
Intervention: Ovaleap® injector
Number of subjects: 180
Study: 27859353

Group type: EXPERIMENTAL
Intervention: Standard intervention (8 session group Triple P)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Brief intervention (3 session discussion group)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Brief and standard interventions
Number of subjects: 69
Study: 24909241

Group type: EXPERIMENTAL
Intervention: Fresh frozen bone (FFB) allograft in chips
Number of subjects: 20

Group type: COMPARATOR
Intervention: Autogenous bone from the mandibular ramus
Number of subjects: 20
Study: 25093728

Group type: EXPERIMENTAL
Intervention: Educational poster displayed in classrooms for 2 weeks (intervention group, 364 students)
Number of subjects: 671

Group type: COMPARATOR
Intervention: No display of educational posters (control group, 305 students)
Number of subjects: 671
Study: 22004689

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg nightly for 12 months
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo nightly for 12 months
Number of subjects: 33
Study: 19179556

Group type: EXPERIMENTAL
Intervention: Docetaxel plus cisplatin and fluorouracil (TPF)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Cisplatin and fluorouracil (PF)
Number of subjects: 166
Study: 17242100

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% (w/v)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Bupivacaine 0.25% (w/v)
Number of subjects: 80
Study: 15614540

Group type: EXPERIMENTAL
Intervention: Transpalpebral tonometer TGDc-01
Number of subjects: 103

Group type: COMPARATOR
Intervention: Goldmann applanation tonometry
Number of subjects: 103
Study: 12185774

Group type: EXPERIMENTAL
Intervention: Specialist nursing intervention; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not specified.
Number of subjects: 0
Study: 9526211

Group type: EXPERIMENTAL
Intervention: 40 mg enoxaparin subcutaneously once per day
Number of subjects: 246

Group type: COMPARATOR
Intervention: 5,000 IU heparin sodium subcutaneously 3 times daily (increased to 7,500 IU if PTT did not reach 40 seconds)
Number of subjects: 246
Study: 8015647

Group type: EXPERIMENTAL
Intervention: Prostacyclin
Number of subjects: 17
Study: 2718920

Group type: EXPERIMENTAL
Intervention: Low selenium intake (18 +/- 1 micrograms/d) for 30 days
Number of subjects: 16

Group type: COMPARATOR
Intervention: Adequate selenium intake (119 +/- 1 micrograms/d)
Number of subjects: 16
Study: 1158187

Group type: EXPERIMENTAL
Intervention: Vagotomy and antrectomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Posture effect on gastric emptying
Number of subjects: 0
Study: 30765948

Group type: EXPERIMENTAL
Intervention: Phacoemulsification (PE)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Phacotrabeculectomy (PT)
Number of subjects: 91
Study: 26567123

Group type: EXPERIMENTAL
Intervention: Intensified treatment for type 2 diabetes
Number of subjects: 3810

Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 3810

Group type: EXPERIMENTAL
Intervention: Dipeptidyl peptidase‐4 inhibitors
Number of subjects: 3810

Group type: EXPERIMENTAL
Intervention: Severe episodes of hypoglycaemia
Number of subjects: 3810

Group type: EXPERIMENTAL
Intervention: Non‐severe episodes of hypoglycaemia
Number of subjects: 3810
Study: 26391130

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (quartiles 2-4)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (quartiles 2-4)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Soluble intercellular adhesion molecule-1 (quartiles 2-4)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: D-dimer (quartiles 2-4)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: High-sensitivity C-reactive protein (multivariable adjustment)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Interleukin-6 (multivariable adjustment)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: Soluble intercellular adhesion molecule-1 (multivariable adjustment)
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: D-dimer (multivariable adjustment)
Number of subjects: 396
Study: 23070939

Group type: EXPERIMENTAL
Intervention: Buffered solution with mild alkalinity (pH 7.2-7.4)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Buffered solution with alkalinity (pH 8.2-8.4)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nonbuffered solution (pH 6.2-6.4)
Number of subjects: 36
Study: 20571360

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure variability episodes outside a blood pressure range (higher than 135 or lower than 95 mmHg)
Number of subjects: 5038
Study: 18381307

Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate injection
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bone marrow injection
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 90
Study: 16614408

Group type: EXPERIMENTAL
Intervention: (n‐3) fatty acids supplementation (3.6 g (n‐3) fatty acids/d)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: (n‐3) fatty acids supplementation
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Background diet with high proportion of MUFA
Number of subjects: 162
Study: 12574881

Group type: EXPERIMENTAL
Intervention: 1 g ceftriaxone i.v. 30 min preoperatively
Number of subjects: 83

Group type: COMPARATOR
Intervention: No study medication (control)
Number of subjects: 83
Study: 10936741

Group type: EXPERIMENTAL
Intervention: Menorest
Number of subjects: 0

Group type: COMPARATOR
Intervention: Climara
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 0
Study: 9148635

Group type: EXPERIMENTAL
Intervention: Preventive temporary clipping of the carrying arteries in anterior connecting arterial aneurysms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive temporary clipping of the carrying arteries in middle cerebral arterial aneurysms
Number of subjects: 0
Study: 8420681

Group type: EXPERIMENTAL
Intervention: CA 125 and Transvaginal Ultrasound (TVUS)
Number of subjects: 74000

Group type: COMPARATOR
Intervention: Routine medical care
Number of subjects: 74000
Study: 3080781

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 27

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Non-endogenous depressives
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Endogenous depressives
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Citalopram and Maprotiline
Number of subjects: 27
Study: 2523228

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (0.04 micrograms kg‐1 min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Noradrenaline (0.025 micrograms kg‐1 min‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor with noradrenaline
Number of subjects: 8
Study: 30380926

Group type: EXPERIMENTAL
Intervention: HIV-infected young transgender women
Number of subjects: 0
Study: 28333180

Group type: EXPERIMENTAL
Intervention: PCOS disease label
Number of subjects: 181

Group type: COMPARATOR
Intervention: Overdiagnosis information
Number of subjects: 181
Study: 24621069

Group type: EXPERIMENTAL
Intervention: 4 g of a proprietary mixture of non-starch polysaccharides (NSPs) (Ambrotose® complex)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Rice flour placebo
Number of subjects: 73

Group type: COMPARATOR
Intervention: Sucrose control
Number of subjects: 73
Study: 22700845

Group type: EXPERIMENTAL
Intervention: Training of clinical staff and provision of tailor‐made information resources with a change in clinic policy to universal HIV testing
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Training of clinical staff and provision of tailor‐made information resources without a change in clinic policy
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Universal HIV testing
Number of subjects: 1315

Group type: COMPARATOR
Intervention: Routine universal testing
Number of subjects: 1315
Study: 21712533

Group type: EXPERIMENTAL
Intervention: Low-glycemic index diet and aerobic exercise training (LGI/EX)
Number of subjects: 15

Group type: COMPARATOR
Intervention: High glycemic index diet and aerobic exercise training (HGI/EX)
Number of subjects: 15
Study: 19627930

Group type: EXPERIMENTAL
Intervention: Visual feedback group
Number of subjects: 29

Group type: COMPARATOR
Intervention: No feedback group
Number of subjects: 29
Study: 16881940

Group type: EXPERIMENTAL
Intervention: Higher literacy (>= 9th grade)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Low literacy (<= 8th grade)
Number of subjects: 380
Study: 12050835

Group type: EXPERIMENTAL
Intervention: Ice therapy before chest tube removal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 50
Study: 10326359

Group type: EXPERIMENTAL
Intervention: Experimental group (purchase)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (purchase/rent)
Number of subjects: 144
Study: 7575134

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP) inhalation, 800 micrograms/day, twice daily (group A)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Beclomethasone dipropionate (BDP) inhalation, 800 micrograms/day, four times daily (group B)
Number of subjects: 33
Study: 1720012

Group type: EXPERIMENTAL
Intervention: Clodronate (600 mg iv as a single dose infused over several hours)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clodronate (oral administration, longer-term effects)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clodronate (double-blind cross-over study)
Number of subjects: 0
Study: 7020779

Group type: EXPERIMENTAL
Intervention: Progressive Relaxation (PR) with positive expectancy
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Relaxation Response (RR) with positive expectancy
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-treatment Control (C)
Number of subjects: 48
Study: 31304986

Group type: EXPERIMENTAL
Intervention: Workshop on sensory processing disorders and behaviour management strategies; experience in a multi-sensory environment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Multi-sensory environments
Number of subjects: 9
Study: 28070979

Group type: EXPERIMENTAL
Intervention: Comprehension Booster programme for a 6-week period
Number of subjects: 38

Group type: COMPARATOR
Intervention: Usual teaching
Number of subjects: 38
Study: 25106731

Group type: COMPARATOR
Intervention: FOLFIRI (5-fluorouracil/leucovorin with irinotecan)
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: IRIS (irinotecan plus S-1)
Number of subjects: 426

Group type: COMPARATOR
Intervention: FOLFIRI (5-fluorouracil/leucovorin with irinotecan) in patients who received prior chemotherapy containing oxaliplatin
Number of subjects: 426

Group type: EXPERIMENTAL
Intervention: IRIS (irinotecan plus S-1) in patients who received prior chemotherapy containing oxaliplatin
Number of subjects: 426
Study: 23911170

Group type: EXPERIMENTAL
Intervention: PREDIRCAM eHealth platform
Number of subjects: 15
Study: 21881929

Group type: EXPERIMENTAL
Intervention: Removal of the PLMA in the awake patient in the operating room close to the end of the procedure.
Number of subjects: 120

Group type: COMPARATOR
Intervention: Removal of the PLMA in the recovery room when the patient was awake.
Number of subjects: 120
Study: 16861597

Group type: EXPERIMENTAL
Intervention: MYTRI program implemented with more than 5,000 students
Number of subjects: 12484
Study: 16439468

Group type: EXPERIMENTAL
Intervention: TLR5‐stop polymorphism (dominant-negative)
Number of subjects: 215
Study: 12646120

Group type: EXPERIMENTAL
Intervention: Modified extract of Parietaria judaica pollen (depigmented and glutaraldehyde‐polymerized), treatment schedule: incremental phase of 5 injections and maintenance dosage of 0.5 ml per month, total of 14 injections over 12 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific immunotherapy)
Number of subjects: 30
Study: 10771448

Group type: EXPERIMENTAL
Intervention: Ziprasidone 10 mg day(-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40 mg day(-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40-80 mg day(-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone 40-120 mg day(-1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ziprasidone (various doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8834415

Group type: EXPERIMENTAL
Intervention: 5 mg haloperidol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5 mg haloperidol with nefazodone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nefazodone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nefazodone and haloperidol
Number of subjects: 12
Study: 1731545

Group type: COMPARATOR
Intervention: 1 mL of 0.9% saline
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: 1 mL of 0.5% (5 mg) lidocaine
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: 1 mL of 1% (10 mg) lidocaine
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: 1 mL of 2% (20 mg) lidocaine
Number of subjects: 368
Study: 6439286

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg twice daily for four weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Naproxen 250 mg twice daily for four weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Sulindac 200 mg twice daily for four weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 50 mg a day (diuretic treatment)
Number of subjects: 10
Study: 31714453

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sprint Interval Training (SIT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Continuous Training (CT)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: All training protocols (HIT, SIT, CT)
Number of subjects: 7
Study: 30625023

Group type: EXPERIMENTAL
Intervention: Financial Counseling (FC) intervention including education, financial assistance screening, and an estimation tool for out-of-pocket costs of chemotherapy.
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Financial Counseling (FC) intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 95
Study: 29016721

Group type: EXPERIMENTAL
Intervention: Unit information present, calorie information present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unit information present, calorie information absent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unit information absent, calorie information present
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unit information absent, calorie information absent
Number of subjects: 0
Study: 26566960

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided catheter placement
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nerve stimulation-guided catheter placement
Number of subjects: 210
Study: 25789827

Group type: EXPERIMENTAL
Intervention: Intermediate care
Number of subjects: 286

Group type: COMPARATOR
Intervention: Standard ward care
Number of subjects: 286
Study: 23017609

Group type: EXPERIMENTAL
Intervention: Standard care with music therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 200
Study: 20959312

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study: 18986067

Group type: EXPERIMENTAL
Intervention: Bistable display with shading cues (Rubin's vase illusion)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control bistable display (disc/aperture test)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Vase/face test with shading cues
Number of subjects: 5
Study: 16646127

Group type: EXPERIMENTAL
Intervention: Cognitive training based on PASAT and two new versions of this task
Number of subjects: 15
Study: 14662581

Group type: EXPERIMENTAL
Intervention: Orange juice
Number of subjects: 25

Group type: COMPARATOR
Intervention: Apple juice
Number of subjects: 25
Study: 10962164

Group type: EXPERIMENTAL
Intervention: Maternal prenatal attachment measured by the Prenatal Attachment Inventory (PAI)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maternal prenatal attachment measured by PAI-factors such as interaction and affection
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maternal prenatal attachment measured by PAI-factors such as differentiation of self with the unborn baby
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Maternal responsive behaviour
Number of subjects: 100
Study: 8995042

Group type: EXPERIMENTAL
Intervention: Spouse-aided treatment
Number of subjects: 23

Group type: COMPARATOR
Intervention: Individual behavioral-cognitive therapy
Number of subjects: 23
Study: 1317237

Group type: EXPERIMENTAL
Intervention: Continuing care from the clinic
Number of subjects: 40

Group type: COMPARATOR
Intervention: General practitioners' management with specialist support
Number of subjects: 40
Study: 3981394

Group type: EXPERIMENTAL
Intervention: Adjectives listed with their dictionary definitions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adjectives listed without definitions
Number of subjects: 0
Study: 31005945

Group type: EXPERIMENTAL
Intervention: Getting Older Adults Outdoors (GO-OUT) intervention: 1-day interactive workshop and 10-week group outdoor walking programme (two 1-hour sessions/week)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Workshop and weekly reminders (WR)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: GO-OUT intervention
Number of subjects: 240

Group type: COMPARATOR
Intervention: WR intervention
Number of subjects: 240
Study: 29239682

Group type: EXPERIMENTAL
Intervention: Trivalent seasonal influenza vaccine (15 μg of hemagglutinin per strain)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (phosphate-buffered saline)
Number of subjects: 60
Study: 26968609

Group type: EXPERIMENTAL
Intervention: Tetrax biofeedback games (20 minutes, 3 times a week for 6 weeks)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional rehabilitation training
Number of subjects: 27
Study: 25197826

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention (6 counseling sessions approximately monthly)
Number of subjects: 818

Group type: COMPARATOR
Intervention: Equal-attention control group (6 nutrition sessions)
Number of subjects: 818

Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 818
Study: 22793966

Group type: EXPERIMENTAL
Intervention: Midazolam (0.5mg.kg(‐1)) in 5 mL fruit juice
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fruit juice (control group)
Number of subjects: 100
Study: 20460227

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (Low dose: 85 mg/d)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (Medium dose: 230 mg/d)
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (High dose: 500 mg/d)
Number of subjects: 257